Phase II Human Trial of ViralClear's Anti-Viral for SARS-CoV-2 Coronavirus Underway at 4 Key Trial SitesGlobeNewsWire • 07/13/20
BioSig Submits Application to Systems for Award Management (SAM) with U.S. GovernmentGlobeNewsWire • 07/10/20
ViralClear Pharmaceuticals partners with Albany Molecular Research Inc. on the manufacture of merimepodib active pharmaceutical ingredient development for the potential treatment of COVID-19GlobeNewsWire • 07/08/20
BioSig Technologies, Inc. Announces $17.5 Million Common Stock Only Registered Direct OfferingGlobeNewsWire • 06/24/20
ViralClear Opens Enrollment with First Patient Dosing in Phase II Human Trial of Anti-Viral MMPD Oral Solution for Treatment of COVID-19GlobeNewsWire • 06/17/20
BioSig Technologies, Inc. (BSGM) CEO Ken Londoner on Phase II Human Trials for Broad-Spectrum Oral Anti-Viral for Treatment of COVID-19 (Transcript)Seeking Alpha • 06/09/20
ViralClear adds St. David's HealthCare in Austin, Texas, to its Planned Phase II trial for its Broad-Spectrum Oral Anti-Viral Candidate for COVID-19GlobeNewsWire • 06/05/20
BioSig Technologies’s PURE EP System to be Presented in Heart Rhythm Society 2020 Science SessionsGlobeNewsWire • 06/04/20
Michael R. Dougherty Joins the Board of ViralClear Pharmaceuticals, a majority-owned subsidiary of BioSig Technologies, Inc.GlobeNewsWire • 05/28/20
ViralClear Closes $10.8 Million Equity Financing for Development of COVID-19 Broad-Spectrum Oral Anti-Viral Candidate MerimepodibGlobeNewsWire • 05/20/20
FDA Clears the Investigational New Drug Application to Enable the Phase II Trial of ViralClear’s Merimepodib, Oral Solution to Treat Adult Patients with Advanced COVID-19, to ProceedGlobeNewsWire • 05/18/20
Michael Schmertzler Joins the Board of ViralClear Pharmaceuticals, a Majority-Owned Subsidiary of BioSig Technologies, Inc.GlobeNewsWire • 05/07/20
Biotech and Investment Veteran Dennis Purcell Joins the Board of ViralClear Pharmaceuticals, a majority-owned subsidiary of BioSig Technologies, Inc.GlobeNewsWire • 05/05/20
Could This Under-the-Radar Biotech Piggyback on Gilead's Remdesivir Success?The Motley Fool • 05/05/20
BioSig's CEO On Why The Medtech Company Bought An Antiviral Candidate To Fight Coronavirus: 'This Drug Is Really Far Along'Benzinga • 04/28/20
BioSig Subsidiary ViralClear Submits Investigational New Drug Application to the FDA for Phase II Clinical Trials for Merimepodib, an Orally Administered Treatment for Patients with COVID-19GlobeNewsWire • 04/24/20
ViralClear Publishes Comparative In Vitro Data on Merimepodib and Remdesivir Activity Against the COVID-19 Novel Coronavirus in F1000 ResearchGlobeNewsWire • 04/23/20
Tony Zook Joins the Board of ViralClear Pharmaceuticals, a majority-owned subsidiary of BioSig Technologies, Inc.GlobeNewsWire • 04/21/20